Transcatheter Closure of Atrial Septal Defect
Asian Journal of Medicine and Health,
Background: Over the past decade, percutaneous atrial septal defect (ASD) closure has been the preferred treatment option in many clinical programs for ASD. Percutaneous ASD closures with advanced device architecture and distribution have established user experience and process security. The ability to diagnose has also improved. The devices have evolved from the larger fixtures to the reset zone, being easily eliminated with little residual mesh material and comfortable fitting with the surrounding structures. Biodegradable technology has been introduced and will be considered as a future option. The emergence of the use of the ASD closure device over the last forty years includes improvements that reduce the incidence of adverse effects reported over the years. Issues reported in the literature include thrombus formation, air tightness, device insertion, abrasion, residual shunts and nickel hypersensitivity. Modern tools hold medium and long-term data with excellent results. Multi-sized devices securely close simple and complex ASDs that can re-scan, reset, and detect percutaneous advanced delivery procedures. In this review, the most widely used tools and distribution processes are discussed and the tools that show promise for the future.
Conclusion: As the field of transcatheter treatment of atrial septal defects (TC-ASD) and congenital interventional cardiology develops, real-world design studies provide valuable developmental information on aspects of care where there is disagreement about best practices and more research is needed.
- Transcatheter Intervention
How to Cite
Behjati M, Rafiei M, Soltani MH, Emami M, Dehghani M. Transcatheter closure of atrial septal defect with amplatzer septal occluder in adults: immediate, short, and intermediate-term results. J Tehran Heart Cent. 2011;6(2):79–84.
Boutin C, Musewe NN, Smallhorn JF, Dyck JD, Kobayashi T, Benson LN. Echocardiographic follow-up of atrial septal defect after catheter closure by double-umbrella device. Circulation. 1993;88(2): 621–627.
Butera G, Romagnoli E, Carminati M, et al. Treatment of isolated secundum atrial septal defects: impact of age and defect morphology in 1,013 consecutive patients. Am Heart J. 2008;156(4):706–712.
Crawford GB, Brindis RG, Krucoff MW, Mansalis BP, Carroll JD. Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. Catheter Cardiovasc Interv. 2012;80(2):157–167.
El-Said H, Hegde S, Foerster S, et al. Device therapy for atrial septal defects in a multi-center cohort: acute outcomes and adverse events. Catheter Cardiovasc Interv. 2015;85(2):227–233.
Freixa X, Ibrahim R, Chan J, et al. Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale. EurIntervention. 2013;9(5):629–635.
Godart F, Houeijeh A, Recher M, et al. Transcatheter closure of atrial septal defect with the figulla ASD occluder: a comparative study with the Amplatzer Septal Occluder. Arch Cardiovasc Dis. 2015;108(1):57–63.
Jones TK, Latson LA, Zahn E, et al. Results of the US multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects. J Am Coll Cardiol. 2007;49(22):2215–2221.
Kaya M, Akpek M, Celebi A, et al. Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale. EuroIntervention. 2014;10:626–631.
Morgan G, Lee KJ, Chaturvedi R, Benson L. A biodegradable device (BioSTAR) for atrial septal defect closure in children. Catheter Cardiovasc Interv. 2010;76 (2):241–245.
Nugent AW, Britt A, Gauvreau K, Piercey GE, Lock JE, Jenkins KJ. Device closure rates of simple atrial septal defects optimized by the STARFlex Device. J Am Coll Cardiol. 2006;48(3):538–544.
Pavlovic M, Buellesfeld L, Meier B. Tools and techniques: PFO/ASD closure. EuroIntervention. 2014;7(3):66–69.
Prokselj K, Kozelj M, Zadnik V, Podnar T. Echocardiographic characteristics of secundum-type atrial septal defects in adult patients: implications for percutaneous closure using Amplatzer septal occluders. J Am Soc Echocardiogr. 2004;17(11):1167–1172.
Kutty S, Hazeem AA, Brown K, et al. Long-term (5- to 20-year) outcomes after transcatheter or surgical treatment of hemodynamically significant isolated secundum atrial septal defect. Am J Cardiol. 2012;109(9):1348-52.
Ostermayer SH, Srivastava S, Doucette JT, et al. Malattached septum primum and deficient septal rim predict unsuccessful transcatheter closure of atrial communications. Catheter Cardiovasc Interv. 2015;86(7):1195-203.
Nishida H, Nakatsuka D, Kawano Y, Hiraiwa N, Takanashi S, Tabata M. Outcomes of totally endoscopic atrial septal defect closure using a glutaraldehyde-treated autologous pericardial patch. Circ J. 2017;81(5):689-93.
Kaya Y, Yurtdas M, Ceylan Y, et al. [Percutaneous closure of secundum atrial septal defects in pediatric and adult patients: short- and mid-term follow-up results] [Turkish]. Turk Kardiyol Dern Ars. 2013;41(8):705-13.
Humenberger M, Rosenhek R, Gabriel H, et al. Benefit of atrial septal defect closure in adults: impact of age. Eur Heart J. 2011; 32(5):553-60.
Salehian O, Horlick E, Schwerzmann M, et al. Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects. J Am Coll Cardiol. 2005;45(4):499-504.
Abstract View: 75 times
PDF Download: 25 times